IP Library Granted Patent US 12,497,664
Granted Patent B2
US 12,497,664 · App. 18/332,648 · Granted Dec 16, 2025

Biomarker panel and methods for detecting microsatellite instability in cancers

Inventors: Bram De Craene (Mechelen, BE); Klaas Decanniere (Mechelen, BE); Jan Van De Velde (Mechelen, BE); Geert Maertens (Mechelen, BE)
Assignee: BIOCARTIS NV
C12Q1/6886C12Q2600/156
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,497,664
App. No.
18/332,648
Granted
Dec 16, 2025
Kind
B2
Abstract

The present invention generally relates to the field of cancer, in particular to cancers having microsatellite instability (MSI) and/or mismatch repair (MMR-) deficiency. Examples of such cancers include many colorectal, gastric, and endometrial tumors. Accordingly, the present invention provides a novel diagnostic marker panel for analyzing MSI loci, together with methods and kits of using said panel in the detection of cancers having microsatellite instability (MSI) and/or mismatch repair (MMR-) deficiency.

Claims (30)

1 . A kit for analyzing microsatellite instability (MSI) status of a colorectal, endometrial, ovarian or gastric cancer sample, the kit comprising fluorophore-labeled molecular beacon probes that are designed to specifically hybridize to target nucleic acid regions as mapped to GRCh38/hg38 human reference genome, wherein the target nucleic acid regions comprise:

(i) human DIDO1 gene starting at position chr20:62,905,340 and encompassing a DIDO1 homopolymeric repeat region, the homopolymeric repeat region comprising 11 consecutive adenines in the reference genome;

(ii) human MRE11 gene starting at position chr11:94,479,765, and encompassing a MRE11 homopolymeric repeat region, the homopolymeric repeat region comprising 11 consecutive adenines in the reference genome;

(iii) human SULF2 gene starting at position chr20:47,657,577 and encompassing a SULF2 homopolymeric repeat region, the homopolymeric repeat region comprising 10 consecutive adenines in the reference genome; and

(iv) human ACVR2A gene starting at position chr2:147,926,117 and encompassing an ACVR2A homopolymeric repeat region, the homopolymeric repeat region comprising 8 consecutive adenines in the reference genome,

wherein each fluorophore-labeled molecular beacon probe comprises a different number of consecutive adenines than the target nucleic acid region for which it is designed.

2 . The kit of claim 1 , wherein the target nucleic acid regions further comprise:

(v) human SEC31A gene starting at position chr4:82,864,412 and encompassing a SEC31A homopolymeric repeat region, the homopolymeric repeat region comprising 9 consecutive thymines in the reference genome;

(vi) human BTBD7 gene starting at position chr14:93,241,685 and encompassing a BTBD7 homopolymeric repeat region, the homopolymeric repeat region comprising 10 consecutive adenines in the reference genome; and

(vii) human RYR3 gene starting at position chr15:33,865,341 and encompassing a RYR3 homopolymeric repeat region, the homopolymeric repeat region comprising 10 consecutive adenines in the reference genome.

3 . The kit of claim 2 , wherein the fluorophore-labeled molecular beacon probes comprise SEQ ID NOs: 17, 20, and 21.

4 . The kit of claim 2 , further comprising a positive control sample that comprises nucleic acid comprising one or more of the target nucleic acid regions of claim 2 .

5 . The kit of claim 4 , wherein at least one of the target nucleic acid regions of the positive control sample comprises an indel.

6 . The kit of claim 5 , wherein the positive control sample is derived from cell line HTC116cl.110268743.

7 . The kit of claim 1 , wherein the fluorophore-labeled molecular beacon probes comprise SEQ ID NOs: 15, 16, 18 and 19.

8 . The kit of claim 1 , further comprising a cartridge.

9 . The kit according to claim 8 , wherein the fluorophore-labeled molecular beacon probes are provided inside of the cartridge.

10 . An automated system comprising the kit of claim 1 .

11 . The automated system of claim 10 , wherein the system is adapted to perform PCR.

12 . A biomarker panel for analyzing microsatellite instability (MSI) status in a biological sample, the panel comprising components for detecting each of the following target nucleic acid regions as mapped to GRCh38/hg38 human reference genome, wherein the target nucleic acid regions comprise:

(i) human DIDO1 gene starting at position chr20:62,905,340 and encompassing a DIDO1 homopolymeric repeat region, the homopolymeric repeat region comprising 11 consecutive adenines in the reference genome;

(ii) human MRE11 gene starting at position chr11:94,479,765, and encompassing a MRE11 homopolymeric repeat region, the homopolymeric repeat region comprising 11 consecutive adenines in the reference genome;

(iii) human SULF2 gene starting at position chr20:47,657,577 and encompassing a SULF2 homopolymeric repeat region, the homopolymeric repeat region comprising 10 consecutive adenines in the reference genome; and

(iv) human ACVR2A gene starting at position chr2:147,926,117 and encompassing an ACVR2A homopolymeric repeat region, the homopolymeric repeat region comprising 8 consecutive adenines in the reference genome,

wherein the components are fluorophore-labeled molecular beacon probes, and

wherein each fluorophore-labeled molecular beacon probe comprises a different number of consecutive adenines than the target nucleic acid region for which it is designed.

13 . The panel of claim 12 , wherein the target nucleic acid regions further comprise:

(v) human SEC31A gene starting at position chr4:82,864,412 and encompassing a SEC31A homopolymeric repeat region, the homopolymeric repeat region comprising 9 consecutive thymines in the reference genome;

(vi) human BTBD7 gene starting at position chr14:93,241,685 and encompassing a BTBD7 homopolymeric repeat region, the homopolymeric repeat region comprising 10 consecutive adenines in the reference genome; and

(vii) human RYR3 gene starting at position chr15:33,865,341 and encompassing a RYR3 homopolymeric repeat region, the homopolymeric repeat region comprising 10 consecutive adenines in the reference genome.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 21, 2025
From: DE CRAENE, BRAM; DECANNIERE, KLAAS; VAN DE VELDE, JAN; MAERTENS, GEERT
To: BIOCARTIS NV
Reel/Frame 072615/0375 →
SECURITY INTEREST Recorded Oct 31, 2023
From: BIOCARTIS NV
To: GLAS TRUST CORPORATION LIMITED
Reel/Frame 065411/0175 →
Priority Claims (2)
EP 18153056 · Jan 23, 2018 · regional
EP 18168304 · Apr 19, 2018 · regional
Continuity (2)
Division 16767968
Related Publication 20240043938A1 · Feb 8, 2024
References Cited (29)
US 20040110154A1 · Baxter · 2004 [cited by examiner]
US 20090023134A1 · Sidransky · 2009 [cited by examiner]
US 20110165579A1 · Indra · 2011 [cited by examiner]
US 20150045369A1 · Lambrechts · 2015 [cited by examiner]
EP 1904234B1 · 2011 [cited by applicant]
EP 1896180B1 · 2011 [cited by applicant]
EP 2419705A1 · 2012 [cited by applicant]
WO 2006047412A2 · 2006 [cited by applicant]
WO 2007004103A1 · 2007 [cited by applicant]
WO 2013153130A1 · 2013 [cited by applicant]
WO 2017050934A1 · 2017 [cited by applicant]
NEB catalog (1998/1999 pp. 121, 284). [cited by examiner]
Schwarzenbach (Clinical Science (2016) 130, 1559-1569; cited in IDS). [cited by examiner]
Boland, C. et al., A National Cancer Institute Workshop on Microsatellite Instability for Cancer Detection and Familial Predisposition: Development of International Criteria for the Determination of Microsatellite Insta… [cited by applicant]
Bonneville, R. et al., Landscape of Microsatellite Instability Across 39 Cancer Types, JCO Precision Oncology, 2017, pp. 1-15. [cited by applicant]
Buhard, O. et al., Multipopulation Analysis of Polymorphisms in Five Mononucleotide Repeats Used to Determine the Microsatellite Instability Status of Human Tumors, Journal of Clinical Oncology, 2006, 24(2):241-251. [cited by applicant]
Campbel, B. et al., Comprehensive Analysis of Hypermutation in Human Cancer, Cell, 2017, 171(5):1042-1056. [cited by applicant]
Cortes-Ciriano, I. et al., A Molecular Portrait of Microsatellite Instability Across Multiple Cancers, Nature Communications, 2017, 8:15180, pp. 1-12. [cited by applicant]
De Craene, B. et al., Detection of Microsatellite Instability (MSI) with a Novel Panel of Biomarkers in Gastric Cancer Samples, http://biocartis.com/sites/default/files/2018-10/de_craene_b._et_al_idylla_msi_in_gastric_s… [cited by applicant]
Ellegren, H., Microsatellites: Simple Sequences with Complex Evolution, Nature Reviews Genetics, 2004, 5:435-445. [cited by applicant]
Endris, V. et al., Abstract 3735: Detection of Microsatellite Instable Colorectal Cancers from Routine NGS Panel Sequencing Data, Proceedings of the American Association for Cancer Research Annual Meeting, 2017, Cancer … [cited by applicant]
International Searching Authority. International Search Report and Written Opinion, PCT/EP2019/051515, Feb. 25, 2019, 12 pages. [cited by applicant]
Le, D. et al., PD-1 Blockade in Tumors with Mismatch-Repair Deficiency, New England Journal of Medicine, 2015, 372(26):2509-2520. [cited by applicant]
Llosa, N. et al., The Vigorous Immune Microenvironment of Microsatellite Instable Colon Cancer is Balanced by Multiple Counter-Inhibitory Checkpoints, Cancer Discovery, 2015, 5(1):43-51. [cited by applicant]
Maruvka, Y. et al., Analysis of Somatic Microsatellite Indels Identifies Driver Events in Human Tumors, Nature Biotechnology, 2017, 35(10):951-959. [cited by applicant]
Murphy, K. et al., Comparison of the Microsatellite Instability Analysis System and the Bethesda Panel for the Determination of Microsatellite Instability in Colorectal Cancers, Journal of Molecular Diagnostics, 2006, 8… [cited by applicant]
Turajlic, S. et al. Insertion-and-Deletion-Derived Tumour-Specific Neoantigens and the Immunogenic Phenotype: A Pan-Cancer Analysis, Lancet Oncology, 2017, 18:1009-1021. [cited by applicant]
Webber, E. et al., Systematic Review of the Predictive Effect of MSI Status in Colorectal Cancer Patients Undergoing 5FU-Based Chemotherapy, BMC Cancer, 2015, 15:156, pp. 1-12. [cited by applicant]
Zhao, H. et al., Mismatch Repair Deficiency Endows Tumors with a Unique Mutation Signature and Sensitivity to DNA Double-Strand Breaks, eLife, 2014, 3:e02725, pp. 1-26. [cited by applicant]